NASDAQ:SABS SAB Biotherapeutics Q3 2024 Earnings Report $3.79 -0.14 (-3.56%) As of 08/28/2026 04:00 PM Eastern ProfileEarnings HistoryForecast SAB Biotherapeutics EPS ResultsActual EPS-$1.12Consensus EPS -$1.07Beat/MissMissed by -$0.05One Year Ago EPSN/ASAB Biotherapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.50 millionBeat/MissN/AYoY Revenue GrowthN/ASAB Biotherapeutics Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time7:00AM ETUpcoming EarningsSAB Biotherapeutics' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly Report(10-Q) SAB Biotherapeutics Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)August 8, 2026 | theglobeandmail.comSAB BIO Reports Q2 2026 Financial Results and Provides Business HighlightsAugust 6, 2026 | globenewswire.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.August 30 at 1:00 AM | Paradigm Press (Ad)SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 AssessmentJuly 15, 2026 | finance.yahoo.comSAB Biotherapeutics advances SAB-142 Type 1 diabetes trialJuly 12, 2026 | theglobeandmail.comSAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 DiabetesJuly 7, 2026 | finanznachrichten.deSee More SAB Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email. Email Address About SAB BiotherapeuticsSAB Biotherapeutics (NASDAQ:SABS) is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use. The company’s lead programs are directed primarily at infectious diseases. SAB-185, its anti-SARS-CoV-2 polyclonal antibody candidate, advanced through clinical trials for the treatment and prevention of COVID-19. In addition to its coronavirus program, SAB Biotherapeutics is exploring pipeline candidates against other emerging pathogens, including Zika virus, MERS, and chikungunya virus. Beyond infectious disease, the Tc Bovine® platform has potential applications in oncology and chronic inflammatory conditions, where diverse antibody repertoires may address antigenic variation and tumor heterogeneity. Since its founding in 2008, SAB Biotherapeutics has pursued strategic collaborations with government agencies, academic institutions, and industry partners to accelerate development of its antibody therapeutics. The company operates its biomanufacturing and research facilities in Sioux Falls and maintains collaborations across the United States for preclinical and clinical studies. By leveraging its transchromosomic cattle system, SAB Biotherapeutics aims to provide a rapid response capability for emerging public-health threats, while building a diversified pipeline of immune-based therapies for multiple indications.View SAB Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekRubrik’s AI Security Bet Could Power the Next Leg HigherIREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings3 Financial Stocks Positioned for the Fed’s Next Move After Jackson HoleNutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
